CCCDTD5: research diagnostic criteria for Alzheimer’s Disease

Serge Gauthier1 | Howard Chertkow2 | Joseph Theriault1 | Céline Chayer3 | Marie-Chantal Ménard4 | Guy Lacombe5 | Pedro Rosa-Neto1 | Zahinoor Ismail6

1 McGill Center for Studies in Aging, Montreal, Canada
2 Baycrest Health Sciences, Toronto, Canada
3 Département de Neurologie, Université de Montréal, Montréal, Canada
4 Centre Hygie, Saint-Jean-sur-Richelieu, Canada
5 Département de médecine, Service de gériatrie, CIUSSS de l’Estrie-CHUS, Université de Sherbrooke, Sherbrooke, Canada
6 Hotchkiss Brain Institute and O’Brien Institute for Public Health, University of Calgary, Calgary, Canada

Correspondence
Dr Serge Gauthier, McGill Center for Studies in Aging, 6825 LaSalle Boulevard, Montreal, QC, Canada, H4H 1R3.
Email: serge.gauthier@mcgill.ca

Abstract

The CCCDTD5 reviewed the research diagnostic criteria for Alzheimer’s disease proposed in the NIA-AA Research Framework and supports their use in research but not in clinical practice.

KEYWORDS
Alzheimer, criteria, diagnosis, research

1 | INTRODUCTION

The first Canadian Consensus Conference on the Diagnosis and Treatment of Dementia took place in 1989 and put emphasis on history taking, physical examination, a basic set of laboratory tests, indications for a head computerized scan, and for a referral to a specialist.1

The second CCCDTD in 1998 reaffirmed these recommendations,2;3 using the definition of Alzheimer’s Disease (AD) proposed by the NINCDS-ADRDA Work Group.4

The third CCCDTD in 2006 reaffirmed the clinical diagnosis by primary care practitioners as the main strategy for timely diagnosis, adding that brief cognitive tests such as the Montreal Cognitive Assessment may be more accurate than the Mini Mental State Examination in discriminating between dementia and the normal state, whereas neuropsychological testing may be useful in the differential diagnosis of dementia and other syndromes of cognitive impairment, that B12 serum levels should be determined in all older adults suspected of cognitive decline or dementia.5

The fourth CCCDTD in 2012 had to deal with the shift to an earlier diagnosis of AD in its prodromal stage6 and the definition of AD proposed by the National Institute on Aging – Alzheimer Association (NIA-AA) Work Groups in the preclinical stage,7 the mild cognitive impairment stage8 and the dementia stage,9 all these criteria using biomarkers. The consensus reached in 2012 was that the NIA-AA criteria for AD should be adopted for use in research settings. Additional recommendations were made regarding the diagnosis of early onset dementia, and about rapidly progressive dementia, which should lead to referral to specialty clinics.

The fifth CCCDTD in 2019 studied the research definition of AD proposed by the NIA-AA Research Framework,10 in addition to seven other topics summarized in a core article.11 The current article goes more in details on the reasons we supported this framework, but for research only.
2 | THE NIA-AA RESEARCH FRAMEWORK

The NIA-AA Research Framework proposed a biological definition of AD, intended for observational and interventional research, not routine clinical care. The diagnosis of AD would not be based on the clinical consequences of the disease (i.e., symptoms/signs), but rather on biomarkers of β amyloid deposition, pathologic tau accumulation and neuronal injury (AT(N)). The NIA-AA framework extends the neuropathological definition of AD (abnormal amyloid-β and tau) to living individuals with the use of in vivo amyloid-β (A) and tau (T) biomarkers. Amyloid and tau biomarkers are used to identify AD as a unique biological process that contributes to cognitive decline. The N is placed in brackets as it is not unique to AD and is instead a feature of all neurodegenerative diseases. The authors did emphasize that it was premature and inappropriate to use this research framework in general medical practice.

A concern about the AT(N) definition of AD is the use of the medical term Alzheimer’s ‘disease’ in asymptomatic persons who are amyloid and tau positive, whereas the natural history of progression to symptoms remains uncertain. However, one might claim that a diagnosis of AD in predementia stage if the disease legitimizes early therapeutic interventions targeting disease pathophysiology.

Another critique to the AT(N) system refers to a certain disregard to co-pathologies such as cerebrovascular disease, neuro-inflammation or age-related protein aggregates such as transactive response DNA binding protein 43 kDa (TDP43), and alpha-synuclein. As these co-pathologies might change the course of the disease, it is imperative to recognize them. For example, a recent study conducted in memory clinic patients has highlighted that severe white matter hyperintensities differentiated between A-T+N+ and A+T+N+ cases.

The lack of affordable clinically approved biomarkers for large scale use represents another concern. Although certain amyloid PET agents have clinical certifications, only cerebrospinal fluid biomarkers have obtained clinical certifications for detection of amyloid β42, total tau and phosphorylated tau on the 181 fragment (p-tau-181).

Tau PET agents remain to be approved for clinical use, but there are encouraging reports about plasma p-tau-181 levels correlating with brain amyloid and tau content.

Early results from using the AT(N) classification in observation research databases such as the Alzheimer’s Disease Neuroimaging Initiative (ADNI) demonstrate that AT(N) positivity does predict faster clinical progression from cognitively normal to incident prodromal stage of AD, and from MCI to dementia. Population-based cohort studies also indicate that the AT(N) classification system demonstrates better prediction of memory decline over 5 years than readily available clinical and genetic information. This classification may provide prognostic information useful in targeted recruitment into clinical trials. Another population-based cohort study demonstrated that biologically defined AD is more prevalent than clinically defined AD at any age, and three times more prevalent at age 85 among both women and men. The prevalence of biological AD resembled the prevalence of clinical AD 10+ years later.

Another finding from using primarily in vivo biomarkers to diagnose AD is the number of persons with dementia that are both amyloid and tau negative, indicating that their cognitive decline is due to another etiology. Furthermore, a small percentage of individuals with dementia are amyloid negative but tau positive. This may increase interest in primary age related tauopathy (PART); for the A-T+ dementias, and the limbic-predominant age-related TDP-43 encephalopathy (LATE); for the A-T- group.

3 | RECOMMENDATIONS APPROVED BY THE CCCDTDS

1. We recommend the adoption of the criteria for the biological definition of Alzheimer’s disease proposed by the NIA-AA working group in 2018 only for observational and interventional research.

2. We recommend the addition to this biological definition of other pathological factors such as vascular, inflammatory, synuclein and TDP-43 as soon as there are validated instruments to reliably measure their levels.

3. Given that the presence of brain amyloid and/or tau in cognitively normal people is of uncertain significance, we discourage the use of amyloid and tau imaging without memory decline, outside of the research setting. The medical community should be clear in its discussion with patients, the media and the general population that the presence of brain amyloid and/or tau in normal people is of unclear significance at the present time.

ACKNOWLEDGMENTS

The CCCDTDS meeting was supported financially by the Canadian Consortium on Neurodegeneration in Aging, the Réseau des cliniques mémoire du Québec, the Réseau Québécois de Recherche sur le Vieillissement.
CONFLICT OF INTEREST STATEMENT
The CCCDTD5 was funded solely by academic peer-reviews grants, listed in the acknowledgements.

REFERENCES
1. Organizing Committee, CCCDTD. Assessing Dementia: the Canadian Consensus. CMAJ. 1991;144:851-853.
2. Patterson CJ, Gauthier S, Bergman H, et al. The recognition, assessment and management of dementing disorders: conclusions from the Canadian Consensus Conference on Dementia. CMAJ. 1999;160(Suppl 12):S1-S15.
3. Patterson C, Gauthier S, Bergman H, et al. The recognition, assessment and management of dementing disorders: conclusions from the Canadian Consensus Conference on Dementia. CMAJ. 2001;28(Suppl 1):S1-S16.
4. McKhann G, Drachman DA, Folstein M, Katzman R, Price DL, Stadlan E, et al. Clinical diagnosis of Alzheimer’s disease – Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939-944.
5. Feldman H, Jacova C, Robillard A, et al. Diagnosis and treatment of dementia: 2. Diagnosis. CMAJ. 2008;178:825-836.
6. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer’s disease: revisiting the NINCDS-ADRDA criteria. Lancet Neurology. 2007;6:734-746.
7. Sperling RA, Aisen P, Beckett L, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging – Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:280-292.
8. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging – Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:270-279.
9. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging – Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263-269.
10. Jack CR, Bennett DA, Blennow K, et al. NIA-AA research framework: towards a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14:535562.
11. Ismail Z, Black S, Camicioli R, et al. Recommendations of the 5th Canadian Consensus Conference on the Diagnosis and treatment of Dementia. Alzheimers Dement. 2020;https://doi.org/10.1002/alz.12105.
12. Gomez-Isla T, Frosch MP. The challenge of defining Alzheimer disease based on biomarkers in the absence of symptoms. JAMA Neurol. 2019;76(10):1143-1144.
13. Ossenkoppele R, Lyoo CH, Jester-Broms J, et al. Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease. JAMA Neurol. 2020;77(5):632-642.
14. Gauthier S, Zhang H, Ng, KP, Pascoal TA, Rosa-Neto P. Impact of the biological definition of Alzheimer’s disease using amyloid, tau and neurodegeneration (ATN): what about vascular changes, inflammation, Lewy body pathology? Transl Neurodegener. 2018;31:7-12.
15. Altomare D, de wilde A, Ossenkoppele R, et al. Applying the ATN scheme in a memory clinic population: the ABIDE project. Neurology. 2019;93:e1635-e1646.
16. Karikari TK, Pascoal TA, Ashton NY, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modeling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422-433. S1474-4422(20)30071-5.
17. Yu JT, Li JQ, Suckling J, et al. Frequency and longitudinal clinical outcomes of Alzheimer’s AT(N) biomarker profiles: a longitudinal study. Alzheimers Dement. 2019;15(9):1208-1217. https://doi.org/10.1016/j.alz.2019.05.006.
18. Jack CR, Wiste HJ, Thernau TM, et al. Associations of amyloid, tau, and neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia. JAMA. 2019;321(23), 2316-2325.
19. Jack CR, Thernau TM, Weigand SD, et al. Prevalence of biologically vs clinically defined Alzheimer spectrum entities using the NIA-AA research framework. JAMA Neurol. 2019;https://doi.org/10.1001/jamaneurol.2019.1971.
20. Bell WR, An Y, Kageyama Y, et al. Neuropathology, genetic and longitudinal cognitive profiles in primary age-related tauopathy (PART) and Alzheimer’s disease. Alzheimers Dement. 2019;15:8-16.
21. Nelson PT, Dickson DW, Trojanowski QJ, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus workgroup report. Brain. 2019;42(6):1503-1527. https://doi.org/10.1093/brain/aw2099.

How to cite this article: Gauthier S, Chertkow H, Theriault J, et al. CCCDTD5: Research diagnostic criteria for Alzheimer’s disease. Alzheimers Dement. 2020;6:e12036. https://doi.org/10.1002/trc2.12036